Prenzler Nils K, Salcher Rolf, Lenarz Thomas, Gaertner Lutz, Warnecke Athanasia
Department of Otorhinolaryngology, Head and Neck Surgery, Hanover Medical School, Hanover, Germany.
Cluster of Excellence "Hearing4all2.0" of the German Research Foundation, Hanover, Germany.
Front Neurol. 2020 Apr 15;11:258. doi: 10.3389/fneur.2020.00258. eCollection 2020.
Administration of low-dose steroids via a catheter inserted into the cochlea to apply pharmaceuticals to more apical regions was previously shown not to be sufficient for long-term reduction of electrode impedances. The aim of the present study was to investigate the effect of intra-cochlear high-dose triamcinolone application on impedances in cochlear implant recipients. Patients received low-dose (4 mg/ml; = 5) or high-dose (20 mg/ml; = 5) triamcinolone via a cochlear catheter just prior to the insertion of a Med-El Flex28 electrode. Impedances were measured at defined time points from intra-operatively up to 12 months after first fitting and retrospectively compared with a control group (no steroid application). Patients who received a high-dose application of crystalloid triamcinolone showed significantly reduced impedances in the first fitting measurements compared to the control group. This effect was no longer detectable in patients of the low-dose group at that time. Looking at the different regions of the electrode, the impedance values were lowered significantly only at the basal and medial contacts. At later time points, there were no significant differences between any of the groups. This is the first study to demonstrate a dose-dependent reduction of impedances by deep intra-cochlear injection of triamcinolone in cochlear implant patients. With a high-dose, single application of triamcinolone using a cochlear catheter prior to insertion of a Flex28 electrode, the impedances can be significantly reduced up to and including the first fitting. Although the effect was longer lasting than when compared to low-dose triamcinolone, it was also not permanent.
先前的研究表明,通过插入耳蜗的导管给予低剂量类固醇以将药物应用于更顶端区域,不足以长期降低电极阻抗。本研究的目的是调查耳蜗内高剂量曲安奈德应用对人工耳蜗植入受者阻抗的影响。患者在插入Med-El Flex28电极之前,通过耳蜗导管接受低剂量(4毫克/毫升;n = 5)或高剂量(20毫克/毫升;n = 5)的曲安奈德。在从手术中到首次调试后12个月的特定时间点测量阻抗,并与对照组(未应用类固醇)进行回顾性比较。接受高剂量晶体曲安奈德应用的患者在首次调试测量中与对照组相比,阻抗显著降低。此时低剂量组患者中不再能检测到这种效果。观察电极的不同区域,仅在基底和内侧触点处阻抗值显著降低。在随后的时间点,各组之间没有显著差异。这是第一项证明在人工耳蜗植入患者中通过耳蜗内深部注射曲安奈德可使阻抗呈剂量依赖性降低的研究。在插入Flex28电极之前,使用耳蜗导管单次高剂量应用曲安奈德,阻抗可显著降低,直至并包括首次调试。尽管与低剂量曲安奈德相比,这种效果持续时间更长,但也不是永久性的。